Top

Osteoporosis International

Published in:

01-01-2012 | Original Article

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

Authors: C. W. Rhee, J. Lee, S. Oh, N. K. Choi, B. J. Park

Published in: Osteoporosis International | Issue 1/2012

Abstract

Summary

Concerns have been raised among clinicians and patients whether or not bisphosphonates increase the risk of atrial fibrillation. In this large cohort study, increased risk of atrial fibrillation was not found to be associated with bisphosphonate. In fact, bisphosphonate even showed a protective effect against cardiac arrhythmia compared to other osteoporosis medications.

Introduction

Increased risk of atrial fibrillation among bisphosphonate users has been reported; however, the results from these studies are controversial. The purpose of this study was to evaluate the risk of atrial fibrillation associated with bisphosphonate use in older women.

Methods

We used the Korean Health Insurance Review and Assessment Service claims database from May 1, 2005 to June 30, 2006. Retrospective cohort analysis was conducted on women 65 years or older with newly diagnosed cases of osteoporosis (ICD 10 code: M80, M81) who had not previously taken any medications for osteoporosis. Bisphosphonate-exposed and non-exposed patients were followed until they were either diagnosed with atrial fibrillation (ICD 10 code: I48) or until the end of the study. The Cox proportional hazards model was used to calculate hazard ratios and the 95% confidence intervals.

Results

Atrial fibrillation was reported in 626 of the 120,319 patients (0.52%) treated with bisphosphonates and 66 of 9,863 patients (0.67%) treated with other osteoporosis medications. Overall hazard ratio for developing atrial fibrillation in the bisphosphonate-treated group was 0.52 (95% CIs, 0.29–0.91). In patients with a medication possession ratio greater than 0.7, the hazard ratio was lower (HR 0.41, 95% CIs 0.23–0.75). In the subgroup analysis, alendronate showed a statistically significant protective effect against the risk of atrial fibrillation with a hazard ratio of 0.75 (95% CI, 0.58–0.97).

Conclusion

Among older Korean women with osteoporosis, bisphosphonate was found to have a protective effect against atrial fibrillation.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535–1541PubMedCrossRef

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) study group. JAMA 282:1344–1352PubMedCrossRef

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int 11:83–91PubMedCrossRef

Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420–432PubMedCrossRef

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef

Cummings S, Schwartz A, Black D (2007) Alendronate and atrial fibrillation [Letter]. N Engl J Med 356:1895–1896PubMedCrossRef

Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ (2004) Lifetime risk for development of atrial fibrillation: the framingham heart study. Circulation 110:1042–1046PubMedCrossRef

Kopecky SL, Gersh BJ, McGoon MD, Chu CP, Ilstrup DM, Chesebro JH, Whisnant JP (1999) Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. Arch Intern Med 159:1118–1122PubMedCrossRef

Sørensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336:813–816PubMedCrossRef

10.

Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG, Weiss JP, Lappé DL, Osborn JS, Day JD (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824–828PubMedCrossRef

11.

Huang WF, Tsai YW, Wen YW, Hsiao FY, Kuo KN, Tsai CR (2010) Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause 17:57–63PubMedCrossRef

12.

Abrahamsen B, Eiken P, Brixen K (2009) Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 265:581–592PubMedCrossRef

13.

Loke Y, Jeevanantham V, Singh S (2009) Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 32:219–228PubMedCrossRef

14.

Bhuriya R, Singh M, Molnar J, Arora R, Khosla S (2010) Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 142:213–217PubMedCrossRef

15.

Gates BJ, Sonnett TE, DuVall CA, Dobbins EK (2009) Review of osteoporosis pharmacotherapy for geriatric patients. Am J Geriatr Pharmacother 7:293–323PubMedCrossRef

16.

von der Recke P, Hansen M, Hassager C (1999) The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106:273–278PubMedCrossRef

17.

Fuster V, Rydén LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 48:854–906PubMedCrossRef

18.

Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826–831PubMedCrossRef

19.

Tankó LB, Christiansen C, Cox DA, Geiger MJ, Mcnabb MA, Cummings SR (2005) Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 20:1912–1920PubMedCrossRef

20.

Vasikaran SD (2001) Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 38:608–623PubMedCrossRef

21.

Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139:101–111PubMedCrossRef

22.

Roelofs A, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s–6230sPubMedCrossRef

23.

Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D (1996) Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133–139PubMedCrossRef

24.

Schweitzer D, Oostendorp-Van De Ruit M, Van der Pluijm G, Löwik CW, Papapoulos SE (1995) Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylamino hydroxypropylidene bisphosphonate. J Bone Miner Res 10:956–962PubMedCrossRef

25.

Celiloglu M, Aydin Y, Balci P, Kolamaz T (2009) The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 16:689–693PubMedCrossRef

26.

Kronzon I, Tunick PA (2006) Aortic atherosclerotic disease and stroke. Circulation 114:63–75PubMedCrossRef

27.

Ylitalo R, Mönkkönen J, Urtti A, Ylitalo P (1996) Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med 127:200–206PubMedCrossRef

28.

Ylitalo R, Kalliovalkama J, Wu X, Kankaanranta H, Salenius JP, Sisto T, Lähteenmäki T, Ylitalo P, Pörsti I (1998) Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol 83:125–131PubMedCrossRef

29.

Luckish A, Cernes R, Boaz M, Gavish D, Matas Z, Fux A, Shargorodsky M (2008) Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors. Bone 43:279–283PubMedCrossRef

30.

Montagnani A, Gonnelli S, Cepollaro C, Campagna MS, Franci MB, Pacini S, Gennari C (2003) Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone 32:15–19PubMedCrossRef

31.

Guney E, Kisakol G, Ozgen AG, Yilmaz C, Kabalak T (2008) Effects of bisphosphonates on lipid metabolism. Neuro Endocrinol Lett 29:252–255PubMed

32.

Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E (2000) Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 15:599–604PubMedCrossRef

33.

Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565PubMedCrossRef

34.

Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119(suppl .2):150–162CrossRef

35.

Rodan G, Reszka A, Golub E, Rizzoli R (2004) Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20:1291–1300PubMedCrossRef

36.

Geusens P (2009) Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 7:12–17PubMedCrossRef

37.

Jeong JH (2005) Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years. J Korean Med Sci 20:26–30PubMedCrossRef

Title: Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis
Authors: C. W. Rhee
J. Lee
S. Oh
N. K. Choi
B. J. Park
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 1/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-011-1608-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Impact of a centralized osteoporosis coordinator on post-fracture osteoporosis management: a cluster randomized trial

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass—a randomized controlled 1-year trial

Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis

The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years